YolTech & KACTUS Unite for DNA Editing in China

 



YolTech, a biopharmaceutical company focused on mRNA-LNP delivery for gene editing therapies, has joined forces with KACTUS, a prominent developer in the biopharmaceutical industry, to accelerate the commercialization of YolTech's exclusive DNA editor, YolCas12TM, in Greater China. As part of this partnership, KACTUS will have exclusive rights to produce and sell YolCas12TM.


YolCas12TM is a groundbreaking technology that enables precise modifications at the molecular level, offering unmatched accuracy and efficiency. Its potential applications span across gene therapy and biomedical research, which have already been validated by various collaborative companies. Currently, TolTech has successfully entered the clinical trial phase with this editor.


"We're thrilled to announce this collaboration with KACTUS, which highlights our leadership in genetic innovation," stated Dr. Yuxuan Wu, the Founder and CEO of YolTech. "This milestone demonstrates our dedication to advancing in vivo gene editing and improving patient outcomes."


More Information : https://www.techdogs.com/tech-news/pr-newswire/yoltech-and-kactus-join-forces-to-propel-innovative-dna-editing-system-in-greater-china

Comments

Popular posts from this blog

Aon Unveils $350M Program for Ukraine Recovery

TECNO CAMON 20 Premier 5G and PHANTOM V Flip 5G Secure German Design Awards 2024

Lion Energy Unveils 10W Solar Panel for Portable Power